Search by ticker code:
Generic filters

Search by ticker code:
Generic filters

Search by ticker code:
Generic filters

Is This The ASX’s Healthiest ETF?

One ASX ETF that could boost the returns of an investment portfolio is the ETFS S&P Biotech ETF (ASX: CURE). Below I list some of the opportunities and risks for CURE but first, ETF 101.

About ETFs

Exchange traded funds, or ETFs, are investment funds that are listed on a securities exchange. They can be managed funds or index funds, or in other words, active or passive, and the fees are usually lower than an unlisted investment fund.

To learn more about ETFs, check out the Rask Finance video below or take a free course on the www.raskfinance.com website.

Typically, ETFs give an investor exposure to many different shares or assets with a single purchase, offering one of the quickest and easiest methods of achieving diversification. The Best ETFs Australia website provides a list of all ASX ETFs.

S&P Biotech ETF

The ETFS S&P Biotech ETF is run by a company called ETF Securities (ETFS), Australia’s second-oldest ETF provider.

As the name suggests, this ETF invests in US-based biotechnology companies and is designed to track the performance of the S&P Biotechnology Select Industry Index before fees and expenses.

The ETF has around 124 holdings with the largest holding making up just 2.16% of the portfolio. The two largest holdings are Array BioPharma Inc (NASDAQ: ARRY), a $10 billion company, and Global Blood Therapeutics Inc (NASDAQ: GBT).

In terms of market capitalisation, around 57.1% of the ETF is allocated to small caps and 8.2% to large caps.

This ETF has been operating for less than a year, but year-to-date it has returned 21.83%. Over a five-year period, the index that it tracks has returned 18.29% per annum.

Fees and Risk

The management fee for CURE is 0.45% per year, which is broadly in line with some of the other growth ETFs mentioned in this article, although there are cheaper options around.

The main risk with this ETF is the lack of diversification. Although there are 124 holdings, they are all companies within the same industry. As CURE is an industry-specific ETF, you should think twice about making it a large holding in your portfolio.

The biotech industry also comes with its own set of risks. Most of the companies are heavily research focused, and the fact sheet for this ETF points out that many biotech companies make little or no sales/revenue.

The success of the company can often depend on one breakthrough or regulatory approval, making it a speculative industry.

The current weighted average price-earnings (PE) ratio of the CURE ETF is 29.6 times, while the S&P 500 PE ratio sits around 21 times. This reflects the low earnings and comparatively high prices of these biotech companies.

Summary

The CURE ETF could be an attractive option for growth, but I’d avoid allocating a large percentage of my portfolio due to the concentration in one industry and the speculative nature of biotechnology companies.

For some balance, you might consider pairing this ETF with our number one ETF mentioned in the free report below.

[ls_content_block id=”14948″ para=”paragraphs”]

Disclosure: At the time of writing, Max does not own shares in any of the companies mentioned.

$50,000 per year in passive income from shares? Yes, please!

With interest rates UP, now could be one of the best times to start earning passive income from a portfolio. Imagine earning 4%, 5% — or more — in dividend passive income from the best shares, LICs, or ETFs… it’s like magic.

So how do the best investors do it?

Chief Investment Officer Owen Rask has just released his brand new passive income report. Owen has outlined 10 of his favourite ETFs and shares to watch, his rules for passive income investing, why he would buy ETFs before LICs and more.

You can INSTANTLY access Owen’s report for FREE by CLICKING HERE NOW and creating a 100% FREE Rask Account.

(Psst. By creating a free Rask account, you’ll also get access to 15+ online courses, 1,000+ podcasts, invites to events, a weekly value investing newsletter and more!)

Unsubscribe anytime. Read our TermsFinancial Services GuidePrivacy Policy. We’ll never sell your email address. Our company is Australian owned.

Information warning: The information on this website is published by The Rask Group Pty Ltd (ABN: 36 622 810 995) is limited to factual information or (at most) general financial advice only. That means, the information and advice does not take into account your objectives, financial situation or needs. It is not specific to you, your needs, goals or objectives. Because of that, you should consider if the advice is appropriate to you and your needs, before acting on the information. If you don’t know what your needs are, you should consult a trusted and licensed financial adviser who can provide you with personal financial product advice. In addition, you should obtain and read the product disclosure statement (PDS) before making a decision to acquire a financial product. Please read our Terms and Conditions and Financial Services Guide before using this website. The Rask Group Pty Ltd is a Corporate Authorised Representative (#1280930) of AFSL #383169.

Skip to content